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Summary 
CD30 is a member of the tumor necrosis factor recep- 
tor superfamily, preferentially expressed by T cells 
producing type 2 helper (Th2) cytoklnes, whose ligand 
(CD3OL) has been identlfled on B cells, activated mac- 
rophages, and a subset of activated T cells. We show 
here that cross-linking CD30 with an agonlstic CD30- 
specific monoclonal antibody, as well as with CD30L+ 
CD8+ T cell clones or CD3OL+ B cells, enhanced HIV 
replication in CD4+ T cells from HIV-Infected indivldu- 
als, and such a potentiatlng effect was inhibited by 
anti-CD30L antibody. The anti-CD3OL antibody also 
exerted a suppressive effect on spontaneous HIV repli- 
cation occurring in lymph node cells from an HIV-sero- 
positive patient, showing CD30L expression by both 
B and CD8+ T lymphocytes. Thus, CD30 trlggerfng by 
CD30L-expressing cells may play an Important role In 
the activation of HIV expression from latently infected 
CD4 + T cells. 
Introduction 
It has been suggested that during HIV infection there is 
a bias toward type 2 helper (ThP)-like responses and hence 
Thl inhibition, which may contribute to the loss of control 
of the immune system over HIV infection, resulting in pro- 
gression to AIDS (Clerici et al., 1993). In recent studies, 
we and others were unable to support the concept of a 
general massive alteration to a Th2 pattern in HIV-infected 
individuals (Maggi et al., 1994a; Graziosi et al., 1994). 
However, large numbers of CD8+ T cell clones showing 
a clear-cut Th2-like cytokine profile were generated from 
both peripheral blood and skin biopsies of subjects in ad- 
vanced phases of HIV infection (Maggi et al., 1994b); 
moreover, we found that HIV replicates preferentially in 
Th2 and ThO rather than Thl CD4+ T cell clones in vitro 
(Maggi et al., 1994a). More recently, we have shown that 
CD4+ T cell clones producing ThP-type cytokines (i.e., Th2 
and, to a lesser extent, ThO cells), but not Thl cells, ex- 
press CD30 (Del Prete et al., 1995) one of the members 
of the tumor necrosis factor-nerve growth factor (TNF- 
NGF) receptor superfamily (Smith et al., 1990; Durkop et 
al., 1992). The ligand for CD30 (CD3OL) has been recently 
cloned and found to be expressed on activated macro- 
phages and a subset of activated T cells (Smith et al., 
1993). In normal conditions there are not CD30+ cells in 
the blood, whereas they are present at scanty number as 
large mononuclear cells with evident nucleolus, mainly 
around the B cell follicles of lymphoid tissues and, to a 
minor degree, at the edge of germinal centers (Stein et al., 
1985). The extracellular portion of CD30 is proteolitically 
cleaved to produce a soluble form of the molecule 
(sCD30), which is released by CD3O-expressing cells in 
vitro and in vivo conditions (Josimovic-Alasevic et al., 
1989). Interestingly, elevated levels of sCD30 have re- 
cently been found in the serum of HIV-infected individuals 
(PiUOlO et al., 1994). Moreover, large numbers of ThP-like 
CD8+ T cell clones generated from HIV-infected individu- 
als also showed CD30 expression and released detectable 
amounts of sCD30 in their supernatants (Manetti et al., 
1994). 
These findings prompted us to investigate the possible 
role of CD30 and CD3OL+ cells in HIV replication. The 
results showed that cross-linking CD30 with either an ago- 
nistic CD30-specific monoclonal antibody (MAb) or fixed 
CD8+ T cells expressing CD3OL potentiated HIV replica- 
tion in T cell lines generated from HIV-infected individuals. 
More importantly, an anti-CDdOL antibody inhibited spon- 
taneous HIV replication in freshly prepared lymph node 
cells from an HIV-seropositive patient. Thus, CDBOL- 
CD30 interactions may play an important role in enhancing 
HIV replication, particularly in lymphoid organs, where cell 
to cell contact can easily occur. 
Ftesults and Discussion 
We first searched for the presence of CD30+ cells in the 
circulation of HIV-infected individuals. Virtually nocirculat- 
ing CD30+ cells were found in either 16 HIV-seropositive 
individuals, examined at different stages of HIV infection, 
or 12 HIV-seronegative controls. However, a variable pro- 
portion of CD4+ T cells (ranging from 5%-15%) in both 
HIV-seroposttive and HIV-seronegative subjects expressed 
CD30 following in vitro expansion in medium containing 
phytohemagglutinin (PHA) and interleukin-2 (IL-2). We 
therefore asked whether triggering of CD30 in naturally 
infected CD4+ T cell lines from HIV-seropositive individu- 
als could play any role in HIV replication. Polyclonal CD4+ 
T cell lines, derived from six HIV-infected individuals (four 
belonging to group II and two to group Ill), and which had 
been selected for their inability to produce p24 Ag sponta- 
neously in their supernatants, were stimulated with the 
combination of an insoluble anti-CD3 plus an insoluble 
anti-CD30 MAb showing agonistic activity. A significant 
increase of p24 Ag production in comparison with T cells 
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Table 1. Synergistic Effect of AntiCD30 Agonistic Antibody on 
AntiCDSlnduced HIV Replication in T Cells from HIV-Infected 
Individuals 
Antibody p24 Ag production 
present in culture @g/IO cells) 
None <IO 
Anti-CD3 49 f 33’ 
Anti-CD30 <lO 
Anti-CD3 + anti-CD30 333 f 133’ 
T cell lineswere generated from HIV-infected individuals by stimulation 
of PEWS (1 x W/ml) with PHA (0.1% v/v) and IL-2 (20 U/ml). T cell 
blasts (1 x W/ml) from six lines selected for showing no spontaneous 
p24 Ag production in their supernatant were cultured IO days later 
for 3 days in presence of insoluble anti-CD3 MAb, insoluble agonistic 
anti-CD30 MAb (MM), or both. Cell-free supematants were then as- 
sayed for p24 Ag content, as described in Experimental Procedures. 
Mean values ( f SD) are reported. 
‘p<o.O05. 
stimulated with anti-CD3 MAb alone was obsewed (Table 
1). In subsequent experiments, polyclonal CD4+ T cell 
lines were also generated from two HIV-infected individu- 
als belonging to group IV, subgroup C-l. In spite of the fact 
that these lines showed spontaneous p24 Ag production, 
stimulation with anti-CD3 plus anti-CD30 MAb again re- 
sulted in a significant increase of p24 Ag production in 
comparison with either unstimulated T cells or T cells stim- 
ulated with anti-CWOor anti-CD3 MAb alone. The kinetics 
of CD30 expression induced by stimulation of T cells from 
one of these lines with the insoluble anti-CD3 MAb is 
shown in Figure 1 a. CD30 expression became evident on 
day 1 and peaked on day 2 after activation. Figure 1 b 
shows the kinetics of p24 Ag production induced in the 
same line by stimulation with anti-CD3 MAb alone or the 
combination of anti-CD3 plus anti-CD30 MAb. The potenti- 
ating effect of anti-CD30 MAb on p24 Ag production was 
also maximal on day 2, clearly paralleling the expression 
of CD30 induced by the anti-CD3 MAb (Figure la). The 
potentiating effect of anti-CD30 MAb on HIV replication 
did neither simply reflect an increase in cell proliferation 
nor a TNFa-mediated stimulation, inasmuch as it was not 
inhibited by either anti-IL-2 or anti-TNFa antibody (data 
not shown). In parallel experiments, we have found that 
CD30 cross-linking induced NF-xB up-regulation in ThO 
and Th2, but not in Thl , CD4+ T cell clones (P. P. McDon- 
ald et al., submitted). This suggests that induction of HIV 
expression by CD30 triggering may result from binding of 
NF-KB transcription factors to KB sites present in the HIV 
long terminal repeat, as it has been shown forthe induction 
of HIV transcription by TNFa (Duh et al., 1989; Poli et al., 
1990; Butera et al., 1993). 
The next obvious question was to establish whether a 
similar potentiating effect on HIV replication could be ex- 
erted by CD30L-expressing cells. Therefore, we tested 
freshly prepared peripheral blood mononuclear cells 
(PBMCs) from normal individuals or patients with chronic 
lymphocytic leukemia (CLL), tonsil mononuclear cells, as 
well as a panel of 20 CD4’ and 15 CD8+ T cell clones, 
for membrane CD3OL expression. Spontaneous CDBOL 
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Figure 1. Kinetics of CD30 Expression Induced by Stimulation with 
Anti-CD3 MAb and of p24 Ag Production Induced by Costimulation 
with Agonistic Anti-CD30 MAb 
Polyclonal Tcell linesweregenerated from an HIV-seropositive individ- 
ual, as reported in the legend of Table 1. On day 10, cells (1 x WY) 
were cultured in the absence or presence of insoluble antiCD3 MAb, 
insoluble antiCD30 MAb, or both. 
(a) Cytoftuorometrtc pattern of CD30 expression by cells examined 
before (time 0) and after l-3 days stimulation with insoluble anti-CD3 
MN values in parentheses represent numbers of CD4+ T cells ex- 
pressing CD30. 
(b) Kinetics of p24 Ag production in parallel unstimulated cultures 
(closed triangle) or cultures stimulated with anti-CD30 MAb (closed 
inverted triangle), anti-CD3 MAb (closed circle) or a combination of 
antiCD3 and anti-CD30 MAb (closed square). 
peripheral blood or tonsil suspensions, as well as in estab- 
lished CD8+, but not in CD4+, T cell clones (data not 
shown). Three CD8+CD30L+ T cell clones, two of which 
were generated from an HIV-seronegative healthy donor 
(SR18 and SR92) and one from an HIV-infected individual 
(lB75), were fixed with paraformaldehyde (0.5%) and co- 
cultured for 48 hr with T cell lines generated from three 
HIV-seropositive individuals in the presence of insoluble 
anti-CD3 MAb. Stimulation with anti-CD3 MAb alone in- 
duced variable production of p24 Ag, but the addition of 
fixed CD8+CD30+, but not of CD8+CD30-, clonal T cells 
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Figure 2. Potentiating Activity of CD8+ T Cell Clones Expressing 
CD8OL on HIV Replication in CD4+ T Cell Lines Generated from HIV- 
Beropositive Individuals 
T cell lines were generated from PBMCs of HIV-infected individuals, 
as described in the legend of Table 1. T cell blasts (1 e/ml) from each 
of three CD8+ CD8OL+ and one CDB+CDXrL- T cell clones were fixed 
with 0.5% paraformaldehyde and cocultured for 48 hr with T blasts 
(W/ml) from each of three different T cell lines in the presence of 
insofuble anti-CD3 MAb and in the absence or in the presence of a 
soluble antiCD8OL MAb (M81). Cell-free supernatants were collected 
and assayed for the content of p24 Ag. Columns represent mean val- 
ues (f SEM) of p24 Ag concentrations. 
promoted consistent and marked increase of p24 Ag pro- 
duction in all three HIV-infected T cell lines, and such a 
potentiating effect was completely inhibited by the addition 
of antiCD30L MAb (Figure 2) whereas the addition of 
an anti-Fas (M3) MAb showing the same isotype had no 
significant inhibitory effect (data not shown). The increase 
of p24 Ag production induced by CD30+ cell8 was about 
10-l 00 time8 higher than that stimulated by the anti-CD30 
MAb, suggesting that CD30 triggering by its natural ligand 
is more effective than triggering by plate-bound anti-CD30 
antibody. Of note also is that one T cell line was generated 
from the same donor of one of the three CD8+CD30L+ T 
cell clones (IB), suggesting that CD30-CD30L interaction 
can promote viral replication in both autologous and allo- 
geneic CD4+T cells. Similar results wereobtained by using 
PBMC from one patient with CLLshowing CD30L+circulat- 
ing cells, whereas PBMC from another patient with CLL 
showing no CD30L+ cells did not induce any increase of 
HIV replication. Interestingly, in these experiments HIV 
replication induced by CD30L+ PBMC was significantly 
higher than that induced in the same system by TNFa. 
Moreover, HIV replication induced by CD30L-CD30 inter- 
action was inhibited by the addition of either antiCD3OL 
MAb or a soluble CD30-lg fusion protein (Figure 3). 
To verify that what occurs in vitro relates to the situation 
in vivo, we finally assessed the expression of CD30L on 
the lymph node biopsy specimen from an HIV-seropositive 
subject. Both the majority of B cells and a proportion of 
CD8+ cells expressed CD3OL (Figure 4a). The CD8+CD3OL+ 
cells were CD3+CD16-, a6’ yS- (data not shown), sug- 
gesting a T cell nature despite the low expression of CD8 
Figure 3. Enhancement of HIV Replication byCD8OL B Lymphocytes 
PBMCs (1 W/ml) from four HIV-infected individuals were stimulated for 
6 days with insolubilized anti-CD3 MAb in absence (open bar) or in 
presenceof CD8OL+ Bcells(lOYml)from aCLLpatient(wide hatching), 
CD8OL+ plus soluble CD80-lg fusion protein (1 rig/ml) (narrow hatch- 
ing), CD8OL’ B cells plus antiCD8OL MAb (M81, 1 pa/ml) (reverse 
hatching), CD8OL- B cells from another CLL patient (closed bar) or 
recombinant TNFa (100 @ml) (stippled bar). Cell-free supernatants 
were collected and assayed for type content of p24 Ag. Columns repre- 
sent mean values ( f SEM)of p24Ag production from the four patients. 
antigen. Interestingly, spontaneous p24 Ag production by 
lymph node cells from the same patient was remarkably 
inhibited (about 50%) by addition in culture of antiCD30L 
MAb, whereas both anti-IL-2 and anti-TNFa MAbs showed 
poor or no inhibitory effect (Figure 4b). In another series 
of experiments, freshly derived PBMC from three HIV- 
serofxrsitive subjects, selected for showing spontaneous 
p24 Ag production, were also incubated with antiCD30L 
MAb or the soluble CD30-lg fusion protein. Spontaneous 
p24 Ag production was partially but consistently inhibited 
by both reagents, whereas neither anti-TNFa MAb nor sol- 
uble CD40-lg fusion protein, used as controls, were inhibi- 
tory(Table2) suggesting that the interaction between HIV- 
infected CD4+CD30+ T cells and cells expressing CDBOL 
can promote HIV replication in vivo, as well. 
Taken together, the results of this study clearly demon- 
strate that CD30 triggering induces HIV expression in in- 
fected CD4+ T cells. This finding is of particular interest 
in view of the demonstration that CD30 is preferentially 
expressed by T cells producing ThP-type cytokines. In- 
deed, if there is induction of a Th2 bias during HIV infection 
(Clerici et al., 1993) rapid killing of ThO/Th2 cells at the 
lymph node level as a consequence of enhanced HIV repli- 
cation Caused by CD30L-CD30 interaction, likely occurs, 
thus accounting for the difficulty of proving the validity 
of the Thl/ThP switch hypothesis (Maggi et al., 1994a; 
Graziosi et al., 1994). The demonstration that elevated 
levels of sCD30 can be found in the serum of HIV-infected 
patients(Pizzolo et al., 1994) is alsoin favorof thispossibil- 
ity. Inasmuch as the increase of serum sCD30 reflects 






Table 2. Inhibitory Effect of Anli-CD3OL MAb and of CD30-lg 
Fusion Pmtein on the Spontaneous p24 Ag Production by 
T Cells from HIV-Infected Individuals 
Nil anti- an& anli- 
CDBOL IL-Z TNF-a 
Figure 4. lnhibitoly Effect of Anti-CD3OL MAb on the Spontaneous 
p24 Ag Production of Lymph Node Cells from an HlV-Sempositive 
Subject 
A biopsy specimen, taken for diagnostic purposes from the cervical 
lymph nodes of an HlV-seropositive subject, was teased and the re- 
sulting cell suspension centrifuged on a Ficoll-Hypaque density gra- 
dient. 
(a) Cell suspensions were examined for the expression ofCD3lIL(MEl) 
by cytofluorimetric analysis, as described in the legend of Figure 1. 
(b) Lymph node cell suspensions were cultured in absence or in pres- 
ence of anti-CD30L (1 pglml), anti-IL-2 (1 @g/ml), or anti-TNFo (1 &ml) 
MAb, and production of p24 Ag was measured in cell-free supernatants 
after 5 days. 
condition8 in which circulating CD30+ cell are not detect- 
able (Josimovic-Alasevic et al., 1989), the elevated level8 
of sCD30 probably result from continuous activation and 
death of CD4+CD30+ Th2/ThO cells. Such a possibility was 
recently substantiated by the demonstration that expres- 
sion of CD30 in CD4+ T cell clones infected with HIV in 
vitro often preceeds, and associates with, early CD4+ T 
cell death (E. M. et al., unpublished data). 
The results of this study also suggest that cells involved 
in HIV replication induced by CD30 triggering may be ei- 
ther 6 cell8 or CD8’ T cells, inasmuch as both cell types 
were found to express the CD30L. However, CD9+ T cells 
usually play a protective role against HIV infection (Brinch- 
mann et al., 1990; Mackewicz and Levy, 1992), at least 
until they do not switch to a less protective functional phe- 
notype (Maggi et al., 1994b; Manetti et al., 1994). There- 
fore, B cells and possibly activated macrophages, which 
have aI80 been shown to express CD3OL mRNA (Smith 
et al., 1993), are more likely responsible for HIV replication 
induced in vivo by CD30L-CD30 interaction. Such a mech- 
anism may be particularly relevant in the activation of HIV 
expression from latently infected CD4+ T cells in lymph 
nodes where B cell/I-h cell contact continuously occurs. 
Finally, the demonstration that blocking CD3OL-CD30 in- 
teraction can markedly suppress the spontaneous p24 Ag 
Reagent 
p24 AQ production @g/ml) 
added in culture Experiment 1 Experiment 2 Experiment 3 
None 114 98 288 
AnliCD3ClL MAb 52 35 139 
Anti-TNF a MAb 120 90 314 
CD3Wg 64 27 ND 
CD40-IQ 105 110 ND 
PBMC from three HIV-infected individuals, selected for their ability to 
produce spontaneously p24 Ag in their supernatant, were cultured for 
6 days in absence or in presence of antiCD30L MAb (M81; lmmunex 
Corporation; 1 pg/ml), anti-TNF a MAb (Genzyme Corporation. Cam- 
bridge, Massachusetts; 1 rglml), CD30-lg (Immunex Corporation; 1 
@ml). or CD40-lg (Immunex Corporation; 1 &ml) fusion protein. 
Production of p24 Ag was measured in cell-free supernatants, as de 
scribed in Experimental Procedures. 
ND, not done. 
production in freshly derived lymph node cells from HIV- 
infected individuals may prompt the consideration of new 
therapeutic strategies for inhibiting HIV replication. 
ExPerImental Procedures 
PHA was purchased from GIBCO Laboratories (Grand Island, New 
York). Recombinant IL-2 was a gift of Eurocetus (Milano, Italy). Anti- 
CD20, antiCD4, antiCD8, antiCD16, anti+TCR, and anti+TCR 
MAbs were purchased from Becton-Dickinson (Mountain View, Califor- 
nia). Anti-CD3 MAb was purchased from Ortho Pharmaceuticals (Rari- 
tan, New Jersey). Anti-IL-2 and anti-TNFa MAbs were purchased by 
Janssen (Beerse, Belgium) and Genzyme Company (Cambridge, Mas- 
sachusetts), respectively. Anti-CD30 MAb (Ber-H2) was purchased by 
DAK0 (Glostrup, Denmark). Anti-CD30 MAb with agonistic activity 
(M44), anti-Fas (M3), antiCD3OL MAbs(MBOand MEl), and the CD3& 
Ig and the CD40-lg fusion protein were provided by lmmunex Corpora- 
tion (Seattle, Washington). 
Subjects 
PBMCs were obtained from 27 HIV-infected patients, 12 HIV- 
seronegative healthy volunteers, and 3 patients with CLL. HIV-infected 
individuals (5) were classified in the group II. 5 in the group Ill, and 
17 in the group IV, according to the Centers for Disease Control (CDC) 
criteria (Centers for Disease Controls and Prevention, lg87). Group 
IV patients (4) belonged to subgroup A, 10 to subgroup C-l, and 3 to 
subgroup D. A biopsy specimen was taken for diagnostic purposes 
from the cervical lymph nodes of a HIV-seropositive subject belonging 
to group Ill. Histological examination revealed a pattern of nonspecific 
adenitis with strong follicular hypsrplasia, suggesting classical HIV- 
related lymphoadenopathy. Mononuclear cells from palatin tonsils of 
a child who underwent tonsillectomy, as well as mononuclear cells 
from three patients with CLL were also used throughout the study. All 
patients and controls gave informed consent. 
Cell Phenotyplng 
CD30 expression by T cells of HIV-infected patients and controls was 
performed on a Cytomn Absolute cytofluorimeter (Orlho Pharmaceuti- 
cals, Raritan, New Jersey) by using fluoresceinated antieD MAb 
and phycoerylhrinated anti-CD4 or anti-CD8 MAb. CD30L expression 
was evaluated by using an anli-CD30L MAb (M81, IgG2b). followed 
by fluoresceinated anti-mouse lg2b goat antibody (Southern Biotech- 
nology Associates; Birmingham, Alabama) and phycoetylhrinated 
anti-CD20 (Leu 16, IgGl), anti-CD4 (Leu 3a, IgGl), or anti-CD8 (Leu 
2a, IgG1) MAbs. 
Generation of 1 Cell Lines snd T Cell Clonem 
T cell lines were generated from 6 HIV-infected individuals by stimula- 
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tion of PBMC (1 x Iv/ml) with PHA (0.1% v/v) and recombinant IL-2 
(20 U/ml). T cell clones were generated from PBMC of one HIV- 
seropositive and one HIV-seronegative by a high efficiency cloning 
technique (Macchia et al., 1993). In brief, PBMCs were seeded under 
limiting dilution conditions (0.3 cell/well) in round-bottomed microwells 
containing 105 irradiated (6.000 rads) allogeneic spleen cells (as feeder 
cells) and PHA (1% v/v) in a final volume of 0.2 ml RPM1 1640 medium 
supplemented with 2 mM Lglutamine, 2 x IO* M 2-ME (complete 
medium) containing human recombinant IL-2 (20 U/ml), and 10% fetal 
calf serum (HyClone Laboratories, Logan, Utah). Growing microcul- 
tures were then supplemented at weekfy intervals with IL-2 (20 U/ml) 
and IO6 irradiated feeder cells. Phenotyping of T cell clones was per- 
formed by using fluorescein-conjugated anti-CD4 and phycoerythri- 
nated anti-CD6 MAbs. 
induction of p24 Ag Productlon by T Cell Lines 
from HIV-Infected tndlvlduals 
T cell blasts (10S/ml) from polyclonal T cell lines generated from HIV- 
infected individuals were cultured for 3 days in presence of insoluble 
anti-CD3 MAb, insoluble anti-CD30 MAb showing agonistic activity 
(M44), or both. T cell blasts (iv/ml) from the same T cell lines were 
also cultured for 2 days with T cell blasts (1 p/ml) from three paraformal- 
dehyde-fixed (0.5%) CD6* CD3OL+ T cell clones in presence or in 
absence of insoluble anti-CD3 MAb. Cell-free supernatants were col- 
lected and assayed for the content of p24 Ag by an appropriate ELISA 
(HIVAG-1 Monoclonal, Abbott; Wiesabaden-Delkenheim, Federal Re- 
public of Germany). 
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